BACKGROUND AND PURPOSE: it is hypothesized that tissue plasminogen activator rescues brain tissue by improving perfusion. In this study, we aimed to examine acute regional perfusion changes and how they influence infarction and clinical outcome. METHODS: three sequential MR scans were performed in 15 tissue plasminogen activator-treated patients within 3.5 (tp1), at 6 hours (tp2), and at 1 month (tp3) after stroke onset. "Hypoperfusion" was defined if mean transit time prolongation was more than a threshold (4 thresholds: 3, 4, 5, and 6 seconds). Four regions of interest were classified: (1) "reperfusion"-hypoperfused at tp1, normal at tp2; (2) "nonreperfusion"-hypoperfused at tp1 and tp2; (3) "normal perfusion"-normal at tp1 and tp2; and (4) "new hypoperfusion"-normal at tp1 and hypoperfused at tp2. Risk of infarction was calculated within each region of interest. Associations between tissue perfusion changes and clinical variables were evaluated using stepwise multiple linear regressions. Moreover, the association between National Institutes of Health Stroke Scale changes and perfusion alterations was assessed using linear mixed effect models. RESULTS: regardless of the mean transit time threshold chosen, the risk of infarction in nonreperfused regions (40% to 68%, thresholds 3 to 6 seconds) was higher than reperfused regions (9% to 30%, P<0.05), and it was higher in new hypoperfusion regions (9% to 33%) than normal perfusion regions (3% to 4%, P<0.05). Volume of new hypoperfusion was significantly associated with onset-to-treatment time and initial hypoperfused volume. Overall relative reperfusion was significantly associated with National Institutes of Health Stroke Scale improvement. CONCLUSIONS: early tissue perfusion changes influenced final tissue fate. The development of new hypoperfusion may result from delay in tissue plasminogen activator and a large initial lesion.
BACKGROUND AND PURPOSE: it is hypothesized that tissue plasminogen activator rescues brain tissue by improving perfusion. In this study, we aimed to examine acute regional perfusion changes and how they influence infarction and clinical outcome. METHODS: three sequential MR scans were performed in 15 tissue plasminogen activator-treated patients within 3.5 (tp1), at 6 hours (tp2), and at 1 month (tp3) after stroke onset. "Hypoperfusion" was defined if mean transit time prolongation was more than a threshold (4 thresholds: 3, 4, 5, and 6 seconds). Four regions of interest were classified: (1) "reperfusion"-hypoperfused at tp1, normal at tp2; (2) "nonreperfusion"-hypoperfused at tp1 and tp2; (3) "normal perfusion"-normal at tp1 and tp2; and (4) "new hypoperfusion"-normal at tp1 and hypoperfused at tp2. Risk of infarction was calculated within each region of interest. Associations between tissue perfusion changes and clinical variables were evaluated using stepwise multiple linear regressions. Moreover, the association between National Institutes of Health Stroke Scale changes and perfusion alterations was assessed using linear mixed effect models. RESULTS: regardless of the mean transit time threshold chosen, the risk of infarction in nonreperfused regions (40% to 68%, thresholds 3 to 6 seconds) was higher than reperfused regions (9% to 30%, P<0.05), and it was higher in new hypoperfusion regions (9% to 33%) than normal perfusion regions (3% to 4%, P<0.05). Volume of new hypoperfusion was significantly associated with onset-to-treatment time and initial hypoperfused volume. Overall relative reperfusion was significantly associated with National Institutes of Health Stroke Scale improvement. CONCLUSIONS: early tissue perfusion changes influenced final tissue fate. The development of new hypoperfusion may result from delay in tissue plasminogen activator and a large initial lesion.
Authors: A V Alexandrov; A M Demchuk; R A Felberg; I Christou; P A Barber; W S Burgin; M Malkoff; A W Wojner; J C Grotta Journal: Stroke Date: 2000-03 Impact factor: 7.914
Authors: Hwa Kyoung Shin; Andrew K Dunn; Phillip B Jones; David A Boas; Michael A Moskowitz; Cenk Ayata Journal: J Cereb Blood Flow Metab Date: 2005-12-07 Impact factor: 6.200
Authors: Gregory W Albers; Vincent N Thijs; Lawrence Wechsler; Stephanie Kemp; Gottfried Schlaug; Elaine Skalabrin; Roland Bammer; Wataru Kakuda; Maarten G Lansberg; Ashfaq Shuaib; William Coplin; Scott Hamilton; Michael Moseley; Michael P Marks Journal: Ann Neurol Date: 2006-11 Impact factor: 10.422
Authors: Marta Rubiera; José Alvarez-Sabín; Marc Ribo; Joan Montaner; Esteban Santamarina; Juan F Arenillas; Rafael Huertas; Pilar Delgado; Francisco Purroy; Carlos A Molina Journal: Stroke Date: 2005-06-09 Impact factor: 7.914
Authors: Stephen M Davis; Geoffrey A Donnan; Mark W Parsons; Christopher Levi; Kenneth S Butcher; Andre Peeters; P Alan Barber; Christopher Bladin; Deidre A De Silva; Graham Byrnes; Jonathan B Chalk; John N Fink; Thomas E Kimber; David Schultz; Peter J Hand; Judith Frayne; Graeme Hankey; Keith Muir; Richard Gerraty; Brian M Tress; Patricia M Desmond Journal: Lancet Neurol Date: 2008-02-28 Impact factor: 44.182
Authors: Natalia Vilor-Tejedor; Iacopo Ciampa; Grégory Operto; Carles Falcón; Marc Suárez-Calvet; Marta Crous-Bou; Mahnaz Shekari; Eider M Arenaza-Urquijo; Marta Milà-Alomà; Oriol Grau-Rivera; Carolina Minguillon; Gwendlyn Kollmorgen; Henrik Zetterberg; Kaj Blennow; Roderic Guigo; José Luis Molinuevo; Juan Domingo Gispert Journal: Alzheimers Res Ther Date: 2021-08-05 Impact factor: 6.982